Mainz Biomed presents its innovations at the gynecology congress in Stuttgart

Mainz Biomed NV, leader in genetic molecular diagnostics for early detection of cancer, will participate as an exhibitor at the Gynecology Congress in Stuttgart on March 1, 2024. This presence underlines the company's commitment to the advancement of colorectal cancer (CRC) screening with ColoAlert®, their innovative diagnostic solution, and recognizes the crucial role of gynecologists in the early detection of this common disease.

In Germany, more than 3 million fecal immunochemical tests (FIT) are performed annually, with gynecologists accounting for 27% of these screenings, behind general practitioners. The congress will provide Mainz Biomed with a unique opportunity to highlight ColoAlert®, an advanced diagnostic tool that detects not only blood in stool samples but also tumor DNA, providing a more comprehensive screening approach compared to FITs traditional.

Mainz Biomed aims to build strong relationships with healthcare professionals to increase brand awareness and integrate ColoAlert® into medical practices for CRC screening. The company will continue to actively participate in relevant medical conferences, including the 130th Congress of the German Society of Internal Medicine in April.